0QLR.L vs. AZN.L

Last updated Apr 2, 2026

Compare and contrast key facts about Novartis AG (0QLR.L) and AstraZeneca plc (AZN.L).

Performance

0QLR.L vs. AZN.L - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in Novartis AG (0QLR.L) and AstraZeneca plc (AZN.L). The values are adjusted to include any dividend payments, if applicable.

0QLR.L vs. AZN.L - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
0QLR.L Novartis AG	11.88%	23.74%	4.99%	5.58%	4.77%	4.00%
AZN.L AstraZeneca plc	10.06%	34.59%	0.92%	-3.53%	32.32%	27.55%

Different Trading Currencies

0QLR.L is traded in GBP, while AZN.L is traded in GBp. To make them comparable, the AZN.L values have been converted to GBP using the latest available exchange rates.

Returns By Period

In the year-to-date period, 0QLR.L achieves a 11.88% return, which is significantly higher than AZN.L's 10.06% return.

0QLR.L

• 1D: 1.42%
• 1M: -4.96%
• YTD: 11.88%
• 6M: 18.64%
• 1Y: 22.46%
• 3Y*: 15.59%
• 5Y*: 9.75%
• 10Y*: —

AZN.L

• 1D: 2.26%
• 1M: -1.51%
• YTD: 10.06%
• 6M: 22.05%
• 1Y: 34.47%
• 3Y*: 12.40%
• 5Y*: 18.41%
• 10Y*: 17.68%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

0QLR.L vs. AZN.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

0QLR.L

0QLR.L Risk / Return Rank: 71
0QLR.L Sharpe Ratio Rank: 75
0QLR.L Sortino Ratio Rank: 67
0QLR.L Omega Ratio Rank: 69
0QLR.L Calmar Ratio Rank: 69
0QLR.L Martin Ratio Rank: 75

AZN.L

AZN.L Risk / Return Rank: 79
AZN.L Sharpe Ratio Rank: 80
AZN.L Sortino Ratio Rank: 77
AZN.L Omega Ratio Rank: 75
AZN.L Calmar Ratio Rank: 80
AZN.L Martin Ratio Rank: 80

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

0QLR.L vs. AZN.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novartis AG (0QLR.L) and AstraZeneca plc (AZN.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	0QLR.L	AZN.L	Difference
Sharpe ratio Return per unit of total volatility	1.07	1.28	-0.21
Sortino ratio Return per unit of downside risk	1.50	1.97	-0.47
Omega ratio Gain probability vs. loss probability	1.21	1.26	-0.04
Calmar ratio Return relative to maximum drawdown	1.47	2.39	-0.92
Martin ratio Return relative to average drawdown	4.72	6.08	-1.36
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

0QLR.L vs. AZN.L - Sharpe Ratio Comparison

The current 0QLR.L Sharpe Ratio is 1.07, which is comparable to the AZN.L Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of 0QLR.L and AZN.L, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	0QLR.L	AZN.L	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.07	1.28	-0.21
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.56	0.78	-0.22
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.73	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.62	0.54	+0.07

Correlation

The correlation between 0QLR.L and AZN.L is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

0QLR.L vs. AZN.L - Dividend Comparison

0QLR.L has not paid dividends to shareholders, while AZN.L's dividend yield for the trailing twelve months is around 1.57%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
0QLR.L Novartis AG	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
AZN.L AstraZeneca plc	1.57%	1.77%	2.23%	2.21%	1.98%	2.33%	2.95%	2.87%	3.44%	4.28%	4.50%	3.95%

Drawdowns

0QLR.L vs. AZN.L - Drawdown Comparison

The maximum 0QLR.L drawdown since its inception was -18.04%, smaller than the maximum AZN.L drawdown of -49.99%. Use the drawdown chart below to compare losses from any high point for 0QLR.L and AZN.L.

Drawdown Indicators

	0QLR.L	AZN.L	Difference
Max Drawdown Largest peak-to-trough decline	-18.04%	-49.99%	+31.95%
Max Drawdown (1Y) Largest decline over 1 year	-14.33%	-15.14%	+0.81%
Max Drawdown (5Y) Largest decline over 5 years	-18.04%	-26.75%	+8.71%
Max Drawdown (10Y) Largest decline over 10 years	—	-26.75%	—
Current Drawdown Current decline from peak	-6.20%	-3.35%	-2.85%
Average Drawdown Average peak-to-trough decline	-5.35%	-11.71%	+6.36%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.10%	5.94%	-0.84%

Volatility

0QLR.L vs. AZN.L - Volatility Comparison

The current volatility for Novartis AG (0QLR.L) is 5.90%, while AstraZeneca plc (AZN.L) has a volatility of 6.97%. This indicates that 0QLR.L experiences smaller price fluctuations and is considered to be less risky than AZN.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	0QLR.L	AZN.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.90%	6.97%	-1.07%
Volatility (6M) Calculated over the trailing 6-month period	13.34%	15.04%	-1.70%
Volatility (1Y) Calculated over the trailing 1-year period	21.56%	26.77%	-5.21%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	17.65%	23.60%	-5.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	17.58%	24.27%	-6.69%

Financials